The Epstein-Barr virus (EBV) is an attractive candidate pathogen for rheumatoid arthritis (RA) because it is persistent, ubiquitous, and has profound effects on the immune system (for review, see Tosato and Blaese'). Its persistence is due to its ability to remain latent in two cell types-the B lymphocyte and the salivary gland epitheliumlboth of which could be envisaged as possible sources for some of the immunological abnormalities in RA. In this review I will examine the link between EBV and RA and attempt to establish whether the link is (a) aetiological, (b) represents an abnormal response to the virus, or (c) whether the serological response to one EBV encoded antigen, which has been termed rheumatoid arthritis nuclear antigen (RANA), gives a clue to the pattern of autoimmunity in RA.
The link between EBV and RA
The link between the virus and the disease may be found in striking parallels between EBV infection and immunopathological events which occur in rheumatoid arthritis. (c Antibodies to EBV determined antigens are raised in sera from patients with RA.
EPSTEIN-BARR VIRUS AS A POLYCI ONAI ACTIVATOR
The Epstein-Barr virus has long been known for its ability to transform B cells into permanent cell lines. Its 17 and in children with juvenile chronic arthritis, though others have found anti-EBVCA titres in RA were the same as those in controls. 19 2 One study which compared anti-EBVCA antibody titres 265 in early RA found them to be normal at presentation,2' though they tended to become raised later in the disease, suggesting that the slight difference in anti-EBVCA titres was acquired either as a result of the disease or its treatment, rather than being due to active EBV infection at the onset of the disease. Two studies found a higher prevalence and titre of antibodies to early antigen," 17 and one found significantly increased titres of antibodies to EBNA. 19 The strongest evidence of a link between EBV and RA was suggested by the description of a fourth, and apparently distinct, antigen, RANA, which was encoded by EBV and which appeared to be a specific target for antibodies in RA. RANA was first described as the SS-C antigen, which, like SS-A and SS-B, was present in the B lymphoblastoid cell line WI-I_2'-and detected by immunodiffusion.
Anti-SS-C was thought to help in the definition of subsets of Sj6gren's syndrome, anti-SS-A and SS-B being associated with primary disease and anti-SS-C with Sjogren's disease with RA. When it appeared that anti-SS-C was equally common in RA without Sjogren's syndrome its name was changed to rheumatoid arthritis precipitin (RAP).> Sera containing RAP also reacted by immunofluorescence with WI-L2 cells giving fine discrete speckles in both nucleus and cytoplasm in cells fixed by air drying. The antigen identified by this technique was called rheumatoid arthritis nuclear antigen. 4 In more recent studies both RAP, antibodies detected by immunodiffusion, and anti-RANA detected by immunofluorescence have acquired the unifying title of anti-RANA. This assumed, without good evidence, that the two methods were detecting the same antibody-antigen system.
EBV in the aetiology of RA
The first studies showed some diagnostic specificity of anti-RANA for RA. When originally described, anti-RANA (as RAP) was detected in 67% of patients and 8% of controls2' (Table) The distinction between RANA and EBNA was later complicated by the description of a least two antigens, EBNA-1 and EBNA-2, which were recognised by anti-EBNA positive sera. EBNA-1 was a highly polymorphic protein whose molecular weight varied in different cell lines from approximately 68 to 90 kilodaltons, the variation being due to a sequence of approximately 20 000 daltons molecular weight termed the internal repeat three (IR3), which consisted entirely of alternating sequences of the amino acids glycine and alanine. In a study by Billings et al,38 confirmed by our laboratory,'9 it was found that anti-RANA antibodies reacted with the EBNA-1 polypeptide by immunoblotting. An explanation for differences between RANA and EBNA was that their respective antibodies reacted with different epitopes on the same polypeptide. A further report decribed synthetic peptides corresponding to sequences in EBNA-1 in enzyme linked immunosorbent assays (ELISA) for measuring specific antibodies.4" Several peptides reacted with RA sera, but the highest levels of binding and the greatest difference between RA and controls were with a peptide, P62, containing glycine and alanine with the sequence GAGGGAGGAGAGGGAGG-AGA, corresponding to part of the IR3 region on EBNA-1. This suggested that P62 contained the epitope binding to anti-RANA antibodies. Sculley et al confirmed that RA sera reacted with EBNA-1 but confused the picture by suggesting that EBNA-2 was the principal target for anti-RANA antibodies, based on correlations with antibodies to RANA by immunofluorescence.4' 42 We have shown43 that -EBNA-2 plays no part in the anti-RANA reaction by demonstrating RANA in a cell line, P3HR-1, in which the EBNA-2 gene has been deleted.44 Furthermore, antibodies purified by affinity chromatography with the peptide P62 reacted with RANA by immunofluorescence. Our study also suggested that although P62 may play a part in the RANA precipitin reaction, other epitopes, possibly even on host proteins, are necessary to produce a precipitin. In our study, like that of Rhodes et al,4" we found higher titres of antibodies to P62 in RA sera than in controls. The same population of RA sera reported previously20" contained almost identical levels of antibodies to EBVCA. This suggested that, like anti-RANA, the sequence containing glycine and alanine represented a selective target for the antibody response in RA.
In our previous study we found that titres of anti-RANA antibodies fell if RA sera were absorbed with cell extracts which did not contain the EBV 
